Literature DB >> 10079271

Up-regulated production and activation of the complement system in Alzheimer's disease brain.

K Yasojima1, C Schwab, E G McGeer, P L McGeer.   

Abstract

We used reverse transcriptase-polymerase chain reaction and Western blotting techniques to measure the levels of complement mRNAs and their protein products in Alzheimer's disease (AD) brain compared with non-AD brain. mRNAs for C1q, C1r, C1s, C2, C3, C4, C5, C6, C7, C8, and C9 were detected in the 11 regions of brain that were investigated. The mRNA levels were markedly up-regulated in affected areas of AD brain. In the entorhinal cortex, hippocampus, and midtemporal gyrus, which had dense accumulations of plaques and tangles, C1q mRNA was increased 11- to 80-fold over control levels, and C9 mRNA 10- to 27-fold. These levels were substantially higher than in the livers of the same cases. Western blot analysis of AD hippocampus established the presence of all of the native complement proteins as well as their activation products C4d, C3d, and the membrane attack complex. These data indicate that high levels of complement are being produced in affected areas of AD brain, that full activation of the classical complement pathway is continuously taking place, and that this activation may be contributing significantly to AD pathology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10079271      PMCID: PMC1866427          DOI: 10.1016/S0002-9440(10)65340-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Complement gene expression in neuroblastoma and astrocytoma cell lines of human origin.

Authors:  D G Walker; P L McGeer
Journal:  Neurosci Lett       Date:  1993-07-09       Impact factor: 3.046

Review 2.  Complement biosynthesis in the central nervous system.

Authors:  S R Barnum
Journal:  Crit Rev Oral Biol Med       Date:  1995

3.  Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease.

Authors:  L Brachova; L F Lue; J Schultz; T el Rashidy; J Rogers
Journal:  Brain Res Mol Brain Res       Date:  1993-06

4.  Clinical trial of indomethacin in Alzheimer's disease.

Authors:  J Rogers; L C Kirby; S R Hempelman; D L Berry; P L McGeer; A W Kaszniak; J Zalinski; M Cofield; L Mansukhani; P Willson
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

5.  Complement and cytokine gene expression in cultured microglial derived from postmortem human brains.

Authors:  D G Walker; S U Kim; P L McGeer
Journal:  J Neurosci Res       Date:  1995-03-01       Impact factor: 4.164

6.  Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders.

Authors:  R N Kalaria; P G Galloway; G Perry
Journal:  Neuropathol Appl Neurobiol       Date:  1991-06       Impact factor: 8.090

7.  Complement activation by beta-amyloid in Alzheimer disease.

Authors:  J Rogers; N R Cooper; S Webster; J Schultz; P L McGeer; S D Styren; W H Civin; L Brachova; B Bradt; P Ward
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

8.  Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections.

Authors:  N Iwamoto; E Nishiyama; J Ohwada; H Arai
Journal:  Neurosci Lett       Date:  1994-08-15       Impact factor: 3.046

9.  Hageman factor and its binding sites are present in senile plaques of Alzheimer's disease.

Authors:  O Yasuhara; D G Walker; P L McGeer
Journal:  Brain Res       Date:  1994-08-22       Impact factor: 3.252

10.  Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines.

Authors:  P Gasque; M Fontaine; B P Morgan
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

View more
  99 in total

Review 1.  Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.

Authors:  Philippe Gasque; Jim W Neal; Sim K Singhrao; Eamon P McGreal; Yann D Dean; Beek Johan Van; B Paul Morgan
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

Review 2.  Cellular cofactors for amyloid beta-peptide-induced cell stress. Moving from cell culture to in vivo.

Authors:  S D Yan; A Roher; A M Schmidt; D M Stern
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

Review 3.  Local neuroinflammation and the progression of Alzheimer's disease.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 4.  Complement in central nervous system inflammation.

Authors:  Scott R Barnum
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 5.  Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.

Authors:  S R Barnum
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

6.  Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease.

Authors:  Qiying Sun; Harald Hampel; Kaj Blennow; Simone Lista; Allan Levey; Beisha Tang; Rena Li; Yong Shen
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

7.  Genetic loci modulating amyloid-beta levels in a mouse model of Alzheimer's disease.

Authors:  Davis Ryman; Yuan Gao; Bruce T Lamb
Journal:  Neurobiol Aging       Date:  2007-04-02       Impact factor: 4.673

Review 8.  Astrocyte-derived extracellular vesicles: Neuroreparative properties and role in the pathogenesis of neurodegenerative disorders.

Authors:  Raghavendra Upadhya; Winston Zingg; Siddhant Shetty; Ashok K Shetty
Journal:  J Control Release       Date:  2020-04-11       Impact factor: 9.776

9.  Gangliosides play pivotal roles in the regulation of complement systems and in the maintenance of integrity in nerve tissues.

Authors:  Yuhsuke Ohmi; Orie Tajima; Yuki Ohkawa; Atsushi Mori; Yasuo Sugiura; Keiko Furukawa; Koichi Furukawa
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

10.  Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

Authors:  Marcel Maier; Ying Peng; Liying Jiang; Timothy J Seabrook; Michael C Carroll; Cynthia A Lemere
Journal:  J Neurosci       Date:  2008-06-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.